Executive function deficits in genetic frontotemporal dementia: results from the GENFI study

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

Executive dysfunction is a core feature of frontotemporal dementia (FTD). Whilst there has been extensive research into such impairments in sporadic FTD, there has been little research in the familial forms.

Methods

752 individuals were recruited in total: 214 C9orf72 , 205 GRN and 86 MAPT mutation carriers, stratified into asymptomatic, prodromal and fully symptomatic, and 247 mutation negative controls. Attention and executive function were measured using the Weschler Memory Scale-Revised (WMS-R) Digit Span Backwards (DSB), the Wechsler Adult Intelligence Scale-Revised Digit Symbol task, the Trail Making Test Parts A and B, the Delis-Kaplan Executive Function System Color Word Interference Test and verbal fluency tasks (letter and category). Linear regression models with bootstrapping were used to assess differences between groups. Correlation of task score with disease severity was also performed, as well an analysis of the neuroanatomical correlates of each task.

Results

Fully symptomatic C9orf72, GRN and MAPT mutation carriers were significantly impaired on all tasks compared with controls (all p<0.001), except on the WMS-R DSB in the MAPT mutation carriers (p=0.147). Whilst asymptomatic and prodromal C9orf72 individuals also demonstrated deficits compared with controls, neither the GRN or MAPT asymptomatic or prodromal mutation carriers showed significant differences. All tasks significantly correlated with disease severity in each of the genetic groups (all p<0.001).

Conclusions

Individuals with C9orf72 mutations show difficulties with executive function from very early on in the disease and this continues to deteriorate with disease severity. In contrast, similar difficulties occur only in the later stages of the disease in GRN and MAPT mutation carriers. This differential performance across the genetic groups will be important in neuropsychological task selection in upcoming clinical trials.

Article activity feed